Liquidia slumps after US court rules for United Therapeutics in patent fight

Liquidia shares plunged nearly 50% on Wednesday after a federal judge ruled that its lung drug infringes key patent held by ​rival United Therapeutics , dealing a major blow to the treatment's ‌commer...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。